Please check your internet connection and try again.
# Mylot%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525at
## Overview
Mylot%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525at (naloxone hydrochloride) is an opioid antagonist. It acts to reverse the effects of opioid agonists, including respiratory depression, sedation, and hypotension.
## Primary Indications
* Treatment of known or suspected opioid overdose, with associated respiratory depression.
## Adult Dosing
* **Intramuscular (IM) or Intravenous (IV) Injection:** 0.4 mg to 2 mg initially. Repeat every 2-3 minutes as needed. If respiratory function does not adequately improve, higher doses may be administered.
* **Intranasal (IN) Spray:** 4 mg in one nostril. Repeat every 2-3 minutes if no response. Dosing frequency and total dose should not exceed available formulations.
* Maximum dose is not well-defined and depends on the extent of opioid exposure.
## Pediatric Dosing
* **IM or IV Injection:** 0.01 mg/kg to 0.1 mg/kg initially. Repeat every 2-3 minutes as needed.
* **IN Spray:** Dosing is typically 4 mg per nostril, but may be adjusted based on clinical assessment and product availability. Consult specific product labeling for pediatric intranasal administration guidance.
* Caution: Dosing may vary based on product concentration.
## Dose Adjustments
* No dose adjustments are typically required for renal or hepatic impairment, as naloxone has minimal accumulation. However, patients with severe impairment may require closer monitoring for recurrent opioid effects.
## Contraindications
* Hypersensitivity to naloxone or any component of the formulation.
## Adverse Effects
* **Common:** Opioid withdrawal symptoms (nausea, vomiting, sweating, abdominal cramps, tachycardia, hypertension, anxiety), increased blood pressure, dizziness, headache, seizures (rare).
* **Serious:** Pulmonary edema (especially with high doses or chronic use), cardiac arrhythmias, hypotension, recurrent respiratory depression.
## Key Drug Interactions
* **Opioid Agonists:** Naloxone directly antagonizes the effects of opioid agonists.
* **Other CNS Depressants:** May potentiate central nervous system effects.
## Monitoring
* Respiratory rate, depth, and pattern.
* Oxygen saturation.
* Level of consciousness.
* Heart rate and blood pressure.
* Observe for signs of recurrent opioid toxicity, especially with long-acting opioids.
## Clinical Pearls
* Naloxone has a shorter duration of action than many opioids; therefore, patients may require repeated doses or continuous infusion, particularly if a long-acting opioid was involved.
* Naloxone should be administered immediately upon suspicion of overdose with respiratory depression.
* The goal of naloxone is to restore spontaneous respiration, not to fully reverse all opioid effects.
* Intranasal naloxone is a viable alternative when IV/IM access is difficult or delayed.
***
*This information is intended for healthcare professionals. Please consult the most current prescribing information and institutional protocols for complete details and guidance. Dosage and administration may vary based on individual patient factors and local guidelines.*
